Pfizer Inc.
PFE,
-2.04%

said Thursday it has received full Food and Drug Administration approval for its Paxlovid oral treatment for COVID-19 for use in adult patients with high risk of developing severe disease. The treatment has been available in the U.S. since December of 2021 under an Emergency Use Authorization. To date, more than 11.6 million treatment courses have been prescribed. There are still about 14,500 reported cases of COVID in the U.S. every week, but many others are not reported. The U.S. ended the COVID public health emergency on May 11. Pfizer’s stock was down 2% Thursday, and has fallen 26% in the year to date, while the S&P 500 has gained 8%.

Source link

You May Also Like

A brief history of throwing food and drink on people as protest

Last weekend, anti-trans campaigner Kellie-Jay Keen-Minshull, better known as Posie Parker, arrived…

Unique hybrid reefs deployed off Miami Beach

BYLINE: Robert C. Jones Jr. and Janette Neuwahl Tannen Newswise — The…

Kevin McCarthy’s Grip on Power Has Never Looked Weaker

Kevin McCarthy Is So Scared He Opened an Impeachment Inquiry | Time…

CDC recommends updated COVID shots for people 6 months of age and older

The Centers for Disease Control and Prevention on Tuesday recommended updated COVID-19…